DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

218 Nucleotides as Regulators of Cellular Function. (Phillis T, ed.)
CRC Press, Boca Raton, FL, 1991, pp. 295–305.
Westfall DP, Todorov LD, Mihaylova-Todorova ST. ATP as
a cotransmitter in sympathetic nerves and its inactivation
by releasable enzymes. J Pharmacol Exp Ther, 2002, 303:
439–444.
Westfall TC. Local regulation of adrenergic neurotransmission.
Physiol Rev, 1977, 57:659–728.
Westfall TC. Prejunctional effects of neuropeptide Y and its role
as a cotransmitter. Exp Pharmacol, 2004, 162:138–183.
Wevers RA, de Rijk-van Andel JF, Brautigam C, et al. A review
of biochemical and molecular genetic aspects of tyrosine
hydroxylase deficiency including a novel mutation (291delC).
J Inherit Metab Dis, 1999, 22:364–373.
Weyer C, Gautier JF, Danforth E. Development of β 3
-adrenoceptor
agonists for the treatment of obesity and diabetes: An
update. Diabetes Metab, 1999, 25:11–21.
SECTION II
Woo AY-H, Wang T-B, Zeng X, et al. Stereochemistry of an agonist
determines coupling preference of β 2
-adrenoceptor to different
G proteins in cardiomyocytes. Mol Pharmacol, 2000,
75:158–165.
Wouters J. Structural aspects of monoamine oxidase and its
reversible inhibition. Curr Med Chem, 1998, 5:137–162.
Wu D, Hersh LB. Choline acetyltransferase: Celebrating its fiftieth
year. J Neurochem, 1994, 62:1653–1663.
Xiao RP, Zhu W, Zheng M, et al. Sutype-specific α 1
- and
β-adrenoceptor signaling in the heart. Trends Pharm Sci, 2006,
27:330–337.
Zhong H, Minneman KP. α 1
-Adrenoceptor subtypes. Eur J
Pharmacol, 1999, 375:261–276.
Zigmond RE, Schwarzschild MA, Rittenhouse AR. Acute regulation
of tyrosine hydroxylase by nerve activity and by neurotransmitters
via phosphorylation. Annu Rev Neurosci, 1989,
12:415–461.
NEUROPHARMACOLOGY